The Director-General of the World Health Organization (WHO) has released the report from the second meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the mpox outbreak of 2024. The meeting took place on November 22, 2024, from…
Genentech, part of the Roche Group, has provided an update on the Phase III SKYSCRAPER-01 study, which evaluated the combination of tiragolumab with Tecentriq® (atezolizumab) compared to Tecentriq alone in patients with PD-L1-high, locally advanced or metastatic non-small cell lung…
Menarini Presents Data at SABCS 2024 Showcasing ORSERDU®’s Potential in ER+/HER2- Metastatic Breast Cancer The Menarini Group and its subsidiary, Stemline Therapeutics, are set to unveil new and expanded findings on ORSERDU® (elacestrant) at the 2024 San Antonio Breast Cancer…
Bicycle Therapeutics to Present Key Zelenectide Pevedotin Data at SABCS 2024 and Share Program Updates Bicycle Therapeutics plc (NASDAQ: BCYC), a company at the forefront of developing a novel therapeutic class based on its proprietary bicyclic peptide (Bicycle®) technology, will…
The Quadripartite organizations – the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO), and the World Organisation for Animal Health (WOAH) – have hailed the adoption of the…
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) at €11.00 per share in cash, representing a fully diluted equity value of €2.0 billion. Despite expressing strong interest in the merger,…
Cancer treatments are evolving, with increasing focus on using the body’s immune defenses to combat the disease. Reetta Virtakoivu, Senior Scientist at Orion, explains how immunotherapy works and why it holds promise for more cancer patients in the future. What…
Versant Ventures has announced the launch of Pep2Tango Therapeutics Inc., a new startup focused on next-generation weight loss treatments. The company will use funds from a significant, undisclosed investment round to advance the development of its innovative unimolecular tetra-receptor agonist…
Altasciences is pleased to have supported Metsera, Inc., a clinical-stage biopharmaceutical company focused on advancing next-generation treatments for obesity and metabolic diseases, in its nonclinical and early-stage clinical trials. This partnership includes a recent Phase I/II trial of MET-097i, an…
Eisai Co., Ltd. has announced the launch of TASFYGO® Tablets 35mg (generic name: tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer harboring FGFR2 gene fusions or rearrangements, who have experienced progression after chemotherapy. The…
On World Children’s Day, the Global Accelerator for Paediatric Formulations Network (GAP-f) highlighted the urgent need for better access to essential medicines for children, particularly in low-resource settings. Despite their vulnerability, children often lack access to age-appropriate medications due to…
Bayer and Cytokinetics, Inc. (Nasdaq: CYTK) have announced a collaboration and license agreement for the exclusive development and commercialization of aficamten in Japan. Aficamten is a cardiac myosin inhibitor being developed for the potential treatment of obstructive and non-obstructive hypertrophic…